Standardgruppe |
Mi
| 01.03.2023 | 14:00 | 16:15 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Detection and identification of bacteria |
| |
Mi
| 01.03.2023 | 16:30 | 18:45 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Diagnostics of viral diseases |
| |
Do
| 02.03.2023 | 08:30 | 10:45 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | The host response in COVID-19 |
| |
Do
| 02.03.2023 | 11:00 | 13:15 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Molecular Diagnostics |
| |
Do
| 02.03.2023 | 14:00 | 16:15 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Update viral hepatitis and HIV |
| |
Do
| 02.03.2023 | 16:30 | 18:45 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Inflammatory response in sepsis and infectious disease |
| |
Fr
| 03.03.2023 | 08:30 | 10:45 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Treatment of viral hepatitis |
| |
Fr
| 03.03.2023 | 11:00 | 13:15 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Pediatric infectious diseases |
| |
Fr
| 03.03.2023 | 14:00 | 16:15 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Fungal infections |
| |
Fr
| 03.03.2023 | 16:30 | 18:45 | SR 76 - Mittel frontal (MC2.L.01.022) | Abhaltung | fix | Infectious disease cases: Clinical chemistry parameters & virologic-serologic diagnostics |
| |